Brain-computer interface company Science Corporation says its retinal implant, which has a 2mm chip, let some blind people read, play cards, and recognize faces
Emily Mullin / Wired :
Context & Ripple Effects
This is an early functional-evidence claim for Science Corporation’s retinal-implant program, centered on what participants could do rather than on a technical specification alone. Subsequent coverage follows that path with a study of the PRIMA implant-and-glasses system reporting restored vision in some patients.
The program’s arc later moves from clinical results toward deployment: Science raised capital to commercialize its blindness implant and eventually received EU approval for Prima in age-related macular degeneration. That makes the reported patient tasks an important early indicator of whether the system could support useful daily activity.
First-order effects
- Science gains a concrete functional-use case for its retinal implant, while the reported participants gain access to tasks involving reading, cards, and face recognition.
- The claim raises the practical standard for evaluating the program: performance is framed in terms of everyday visual capabilities, not just whether an implant produces visual perception.
Second-order effects
- Follow-on clinical work will need to test whether those functional gains are reproducible across patients and settings, as the later PRIMA study begins to do.
- A credible functional benchmark can strengthen Science’s case for the financing, clinical validation, and regulatory work needed to turn an implant system into a treatment.
Third-order effects
- If replicated, retinal neurotechnology could be assessed increasingly by independence-enabling outcomes such as reading and recognition, rather than by device novelty alone.
- The later progression from study results to commercialization funding and approval suggests a broader shift toward implant-plus-wearable systems for restoring specific lost functions, though wider adoption will depend on durable clinical evidence and access pathways.
The trend: Neurotechnology is moving from proving that implants can generate signals toward demonstrating measurable, task-level restoration of human capability.